RhumbLine Advisers’s Crescent Biopharma, Inc. Common Stock CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-10
| Closed | -$294 | – | 4250 |
|
|
2024
Q2 | $294 | Hold |
10
| – | – | ﹤0.01% | 4309 |
|
|
2024
Q1 | $3.13K | Hold |
10
| – | – | ﹤0.01% | 4041 |
|
|
2023
Q4 | $2.46K | Hold |
10
| – | – | ﹤0.01% | 4077 |
|
|
2023
Q3 | $1.57K | Hold |
10
| – | – | ﹤0.01% | 4139 |
|
|
2023
Q2 | $1.82K | Buy |
+10
| New | +$1.82K | ﹤0.01% | 4227 |
|
|
2021
Q2 | – | Sell |
-607
| Closed | -$183K | – | 3039 |
|
|
2021
Q1 | $183K | Hold |
607
| – | – | ﹤0.01% | 2852 |
|
|
2020
Q4 | $228K | Buy |
607
+79
| +15% | +$29.7K | ﹤0.01% | 2782 |
|
|
2020
Q3 | $162K | Sell |
528
-61
| -10% | -$18.7K | ﹤0.01% | 2748 |
|
|
2020
Q2 | $221K | Buy |
589
+147
| +33% | +$55.2K | ﹤0.01% | 2725 |
|
|
2020
Q1 | $101K | Hold |
442
| – | – | ﹤0.01% | 2777 |
|
|
2019
Q4 | $234K | Buy |
442
+3
| +0.7% | +$1.59K | ﹤0.01% | 2696 |
|
|
2019
Q3 | $189K | Sell |
439
-4
| -0.9% | -$1.72K | ﹤0.01% | 2764 |
|
|
2019
Q2 | $528K | Buy |
443
+10
| +2% | +$11.9K | ﹤0.01% | 2337 |
|
|
2019
Q1 | $540K | Sell |
433
-13
| -3% | -$16.2K | ﹤0.01% | 2301 |
|
|
2018
Q4 | $422K | Buy |
446
+144
| +48% | +$136K | ﹤0.01% | 2377 |
|
|
2018
Q3 | $435K | Sell |
302
-18
| -6% | -$25.9K | ﹤0.01% | 2332 |
|
|
2018
Q2 | $516K | Buy |
+320
| New | +$516K | ﹤0.01% | 2301 |
|